StockDrifts LogoStockDrifts

Tetragon Partners GP 13F Portfolio

Portfolio Manager
Tetragon Partners Gp LTD
Performance
+1.88% (2026 Q2)
AUM (13F)
$635.06M
# of Holdings
32
Performance Rank
Allocation (Top 20)
91.2%
Latest filing
Q2 2026

Tetragon Partners Gp LTD Holdings Map

Top 31 Tetragon Partners Gp LTD Holdings

Top 10 holdings

StockCompany% Port.SharesValueActivityOwnershipAvg. CostDate
PATH
UIPATH INC
54.76%30.95M$336.4M
+22.78%(+5.74M)
2025-Q2: 13.72M shares2025-Q3: 16.95M shares2025-Q4: 17.45M shares2026-Q1: 25.21M shares2026-Q2: 30.95M shares
$13.78(+16.15%)
2026-06-30
KGEI
KOLIBRI GLOBAL ENERGY INC
5.51%6.83M$33.8M
+0.00%(+0)
2025-Q2: 7.07M shares2025-Q3: 7.07M shares2025-Q4: 6.93M shares2026-Q1: 6.83M shares2026-Q2: 6.83M shares
$3.90(+43.75%)
2026-06-30
AUTL
AUTOLUS THERAPEUTICS LTD
2.47%9.50M$15.2M
+0.00%(+0)
2025-Q2: 9.50M shares2025-Q3: 9.50M shares2025-Q4: 9.50M shares2026-Q1: 9.50M shares2026-Q2: 9.50M shares
$4.79(-55.11%)
2026-06-30
LYFT
LYFT INC
2.38%1.00M$14.6M
+0.00%(+0)
2025-Q2: 1.00M shares2025-Q3: 1.00M shares2025-Q4: 1.00M shares2026-Q1: 1.00M shares2026-Q2: 1.00M shares
$28.23(-38.08%)
2026-06-30
DFTX
DEFINIUM THERAPEUTICS INC
2.2%287.0K$13.5M
+43.50%(+87.00K)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 200.0K shares2026-Q2: 287.0K shares
$21.03(+102.68%)
2026-06-30
WK
WORKIVA INC
1.97%250.0K$12.1M
+0.00%(+0)
2025-Q2: 150.0K shares2025-Q3: 150.0K shares2025-Q4: 150.0K shares2026-Q1: 250.0K shares2026-Q2: 250.0K shares
$73.33(-3.85%)
2026-06-30
CXM
SPRINKLR INC
1.85%2.20M$11.4M
+0.00%(+0)
2025-Q2: 2.20M shares2025-Q3: 2.20M shares2025-Q4: 2.20M shares2026-Q1: 2.20M shares2026-Q2: 2.20M shares
$10.78(-36.09%)
2026-06-30
MBX
MBX BIOSCIENCES INC
1.83%203.5K$11.2M
+39.91%(+58.06K)
2025-Q2: 0 shares2025-Q3: 177.8K shares2025-Q4: 143.3K shares2026-Q1: 145.5K shares2026-Q2: 203.5K shares
$22.22(+208.65%)
2026-06-30
ALKT
ALKAMI TECHNOLOGY INC
1.77%600.3K$10.9Mnew2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 0 shares2026-Q2: 600.3K shares
$16.86(+22.60%)
2026-06-30
CLDX
CELLDEX THERAPEUTICS INC NEW
1.76%290.4K$10.8M
-7.00%(-21.88K)
2025-Q2: 316.1K shares2025-Q3: 303.6K shares2025-Q4: 243.8K shares2026-Q1: 312.3K shares2026-Q2: 290.4K shares
$26.95(+55.68%)
2026-06-30

About Tetragon Partners Gp LTDโ€™s portfolio

Tetragon Partners Gp LTD reports $635.06M in US-listed equity holdings across 32 positions in its most recent 13F filing. Its largest disclosed positions are PATH (54.8%), KGEI (5.5%) and AUTL (2.5%). The top 20 holdings account for 91.2% of reported assets. Its disclosed equity book has returned +15.06% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.

Portfolio concentration

Portfolio concentration
PATH โ€” 55.0% ($336.43M)KGEI โ€” 5.5% ($33.85M)AUTL โ€” 2.5% ($15.20M)LYFT โ€” 2.4% ($14.61M)DFTX โ€” 2.2% ($13.50M)WK โ€” 2.0% ($12.13M)CXM โ€” 1.9% ($11.35M)MBX โ€” 1.8% ($11.24M)ALKT โ€” 1.8% ($10.88M)CLDX โ€” 1.8% ($10.81M)Other โ€” 23.1% ($141.37M)
77%in top 10
  • PATH55.0%
  • KGEI5.5%
  • AUTL2.5%
  • LYFT2.4%
  • DFTX2.2%
  • WK2.0%
  • CXM1.9%
  • MBX1.8%
  • ALKT1.8%
  • CLDX1.8%
  • Other23.1%

Portfolio changes

What the fund actually did

Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.

New buys
4
ALKTALKAMI TECHNOLOGY INC1.8%
CELCCELCUITY INC1.1%
ACRSACLARIS THERAPEUTICS INC0.3%
GLUEMONTE ROSA THERAPEUTICS INC0.2%
Added to
15
PATHUIPATH INC+22.8%
RLAYRELAY THERAPEUTICS INC+214.1%
IONSIONIS PHARMACEUTICALS INC+132.7%
DFTXDEFINIUM THERAPEUTICS INC+43.5%
+11 more
Trimmed
5
WBDWARNER BROS DISCOVERY INC-72.9%
NKTRNEKTAR THERAPEUTICS-15.6%
CLDXCELLDEX THERAPEUTICS INC NEW-7.0%
AMLXAMYLYX PHARMACEUTICALS INC-6.3%
+1 more

Unlock alerts, watchlists & AI chat

Sign up free to track Tetragon Partners Gp LTD, compare funds side by side, and get alerts the moment positions change.

Source filings

Holdings on this page are parsed from Tetragon Partners Gp LTDโ€™s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1515070). View Tetragon Partners Gp LTDโ€™s 13F filings on SEC

More 13F analyses

View all